FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Nuron | HibTITER
Syndicate content

Nuron buys Hib vaccine from Wyeth, plots relaunch

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Exton, PA-based Nuron is paying an undisclosed sum to purchase Hib vaccine HibTITER from Pfizer's Wyeth unit. The vaccine was previously approved, but Wyeth stopped selling it several years ago after the company reassessed its portfolio. HibTITER helped reduce the incidence of Hib disease in children, Nuron said in a statement, and was among the first glycoconjugate technology vaccines for humans. Nuron execs see the vaccines as a "significant opportunity," and the company is in talks with the FDA to re-launch the shot.

"Nuron has a highly focused product portfolio, and, consequently, we can devote significant attention to educating the medical and regulatory community on the value of this vaccine," explained CEO Shankar Musunuri. "We know the medical milestones achieved with HibTITER and recognize both the medical need and relevance of this vaccine in the U.S. and markets around the world." HibTITER is Nuron's only vaccine candidate.

- here's Nuron's release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Nuron   HibTITER  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.